338 related articles for article (PubMed ID: 6377799)
1. [Action of desoxyfructo-serotonin on Mycobacterium leprae. Results of inoculation of human biopsy specimens in the mouse after a year of treatment].
Ferracci C; Baquillon G; Pattyn SR
Acta Leprol; 1983; 1(4):233-5. PubMed ID: 6377799
[TBL] [Abstract][Full Text] [Related]
2. Mouse foot-pad studies with M. leprae--effect of desoxy fructo serotonin (DFS) and related compounds.
Balakrishnan S; Mester L; Venkataramaniah HN; Bhatia VN
Indian J Lepr; 1985; 57(2):323-8. PubMed ID: 3908578
[TBL] [Abstract][Full Text] [Related]
3. Effect of desoxy fructo serotonin (DFS) on the multiplication of M. leprae in mouse foot-pad.
Balakrishnan S; Mester L; Venkataramanaiah HN; Bhatia VN
Lepr India; 1982 Jan; 54(1):56-8. PubMed ID: 7047899
[No Abstract] [Full Text] [Related]
4. Are viable Mycobacterium leprae present in lepromatous patients after completion of 12 months' and 24 months' multi-drug therapy?
Ebenezer GJ; Daniel S; Norman G; Daniel E; Job CK
Indian J Lepr; 2004; 76(3):199-206. PubMed ID: 15835604
[TBL] [Abstract][Full Text] [Related]
5. Assessment of viability by normal mouse foot-pad and bacillary ATP bioluminescence assay in multibacillary cases treated with an MDT regimen using conventional as well as newer drugs like minocycline and ofloxacin.
Gupta UD; Katoch K; Singh HB; Natrajan M; Sharma VD; Katoch VM
Indian J Lepr; 2000; 72(4):437-42. PubMed ID: 11212477
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of leprosy by human metabolites].
Mester de Parajd L; Mester de Parajd M
Acta Leprol; 1986; 4(3):363-72. PubMed ID: 3105224
[TBL] [Abstract][Full Text] [Related]
7. The mouse foot-pad technique for cultivation of Mycobacterium leprae.
Levy L; Ji B
Lepr Rev; 2006 Mar; 77(1):5-24. PubMed ID: 16715686
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo effects of N-methyl-3,5-dichloro-benzylamine hydrochloride on Mycobacterium leprae.
Dhople AM; Strong LC; Meindl W; Schoenenberger H; Gardner GD
Arzneimittelforschung; 1991 Mar; 41(3):253-6. PubMed ID: 1867663
[TBL] [Abstract][Full Text] [Related]
9. In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Anti-leprosy activity of ofloxacin and ansamycins in mice.
Dhople AM; Ibanez MA
Arzneimittelforschung; 1994 Apr; 44(4):563-5. PubMed ID: 8011013
[TBL] [Abstract][Full Text] [Related]
10. Analysis of quantitative relationship between viability determination in leprosy by MFP, ATP bioluminescence and gene amplification assay.
Gupta UD; Katoch K; Sharma RK; Singh HB; Natragan M; Singh D; Sharma VD; Chauhan DS; Das R; Srivastava K; Katoch VM
Int J Lepr Other Mycobact Dis; 2001 Dec; 69(4):328-34. PubMed ID: 12035294
[TBL] [Abstract][Full Text] [Related]
11. The activity of rifabutin against Mycobacterium leprae.
Yoder LJ; Jacobson RR; Hastings RC
Lepr Rev; 1991 Sep; 62(3):280-7. PubMed ID: 1665534
[TBL] [Abstract][Full Text] [Related]
12. [Desoxyfructo-serotonin: its therapeutic effect in the treatment of leprosy].
Mester de Parajd M; Ambrose EJ; Tayeb N; Antia NH
Acta Leprol; 1989; 7 Suppl 1():200-2. PubMed ID: 2503990
[TBL] [Abstract][Full Text] [Related]
13. Viability of Mycobacterium leprae in lepromatous patients after five years of dapsone monotherapy supplemented with two years of multidrug therapy.
Sivaprasad N; Snehalatha S; Lobo D; Aschhoff M; Job CK
Indian J Lepr; 1995; 67(4):427-33. PubMed ID: 8849919
[TBL] [Abstract][Full Text] [Related]
14. Superiority of the neonatally thymectomized Lewis rat (NTLR) to monitor a clinical trial in lepromatous leprosy of the two regimens of rifampin and dapsone.
Gelber RH; Humphres RC; Fieldsteel AH
Int J Lepr Other Mycobact Dis; 1986 Jun; 54(2):273-83. PubMed ID: 3522770
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of 9 months of treatment of lepromatous leprosy with desoxyfructo-serotonin].
Saint-André P; Baquillon G; Mester de Parajd L; Mester de Parajd M
Acta Leprol; 1982; (86-87):189-97. PubMed ID: 6815988
[No Abstract] [Full Text] [Related]
16. Viability and drug susceptibility testing of M. leprae using mouse footpad in 37 relapse cases of leprosy.
Shetty VP; Wakade AV; Ghate S; Pai VV; Ganapati R; Antia NH
Int J Lepr Other Mycobact Dis; 2003 Sep; 71(3):210-7. PubMed ID: 14608816
[TBL] [Abstract][Full Text] [Related]
17. Drug resistant-Mycobacterium leprae--results of mouse footpad studies from a laboratory in south India.
Ebenezer GJ; Norman G; Joseph GA; Daniel S; Job CK
Indian J Lepr; 2002; 74(4):301-12. PubMed ID: 12624978
[TBL] [Abstract][Full Text] [Related]
18. Activity of ascorbic acid in inhibiting the multiplication of M. leprae in the mouse foot pad.
Hastings RC; Richard V; Christy SA; Morales MJ
Int J Lepr Other Mycobact Dis; 1976; 44(4):427-30. PubMed ID: 798727
[TBL] [Abstract][Full Text] [Related]
19. Mutations in genes related to drug resistance in Mycobacterium leprae isolates from leprosy patients in Korea.
You EY; Kang TJ; Kim SK; Lee SB; Chae GT
J Infect; 2005 Jan; 50(1):6-11. PubMed ID: 15603834
[TBL] [Abstract][Full Text] [Related]
20. Search for effective short-course regimens for the treatment of leprosy.
Pattyn SR
Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):76-81. PubMed ID: 8326183
[No Abstract] [Full Text] [Related]
[Next] [New Search]
